Tag: Ng Kay Ian
XPeng raises USD900m in robotics financing for Dogotix unit
XPeng signs equity financing agreements with several investors for its humanoid robotics business, raising more than USD900 million
Quartet drives Alibaba’s HKD13bn Sun Art Retail sale to DCP
Slaughter and May, Fangda Partners, Sullivan & Cromwell, and JunHe advised on Alibaba’s USD1.7 billion stake sale in Sun Art Retail to DCP Capital
Septet steers ESR Group’s HKD55.2bn delisting
Latham, Kirkland, and Fangda advised on the HKD55.2B ESR Group privatisation, HKEX’s largest take-private deal since 2021
Trio shines on China Oriental-ArcelorMittal USD2.7bn JVs
Fangda Partners, Sullivan & Cromwell, and Baker McKenzie FenXun advised on China Oriental's USD 2.66B steel joint ventures with ArcelorMittal
Fangda, Sullivan & Cromwell act on XPeng buy of Didi’s EV unit
Fangda Partners and Sullivan & Cromwell have advised Chinese electric vehicle maker XPeng on its HKD5.84 billion (USD744 million) acquisition of Didi Global
AIM Vaccine taps S&C and Jingtian on HKD156m listing on HKEX
China’s biggest privately owned vaccine group AIM Vaccine enlisted legal advice from Sullivan & Cromwell (S&C) and Jingtian & Gongcheng for its debut on the HKEX
